How Singular Health’s $1.3M US Deal Could Transform Its Growth Trajectory

Financial Performance and Strategic Focus

Singular Health Group Limited has released its preliminary final report for the year ended 30 June 2025, revealing a net loss after tax of $6.38 million, a significant increase from the $4.92 million loss recorded in the previous year. Despite the widening loss, the company strengthened its balance sheet with a cash position of $13.7 million, bolstered by successful capital raises totaling $11 million during the year.

The financial results reflect the Group's strategic decision to intensify investment in product development, regulatory compliance, and commercial expansion, particularly in the United States market. Revenues from ordinary activities increased modestly to $235,393, driven by growth in 3DICOM software sales, although this was offset by a reduction in research and development grant income following the divestment of its 3D printing subsidiary.

Key US Commercial Partnership

A highlight of FY2025 was the execution of a binding USD $1.3 million commercial agreement with Miami-based Provider Network Solutions (PNS), a Managed Service Organisation serving over 3.7 million patients across Florida, Texas, and Puerto Rico. This partnership aims to deploy Singular Health's 3DICOM software to reduce costly duplicate imaging in the US healthcare system.

The collaboration followed a phased pilot program, including a successful proof-of-concept demonstrating the software's ability to integrate with multiple imaging systems and deliver AI-powered analyses faster than industry benchmarks. The initial deployment targets metropolitan and rural primary care physicians and diagnostic centers, with plans for a national rollout contingent on pilot outcomes.

Technology Advancements and Cloud Migration

During the year, Singular Health completed a significant technical milestone by migrating its 3DICOM platform from a desktop-based product to a cloud-hosted, zero-footprint solution. This transition enables rapid deployment, seamless integration with disparate Picture Archiving and Communication Systems (PACS), and enhanced AI model incorporation, including FDA-cleared dental AI and ongoing breast cancer detection tools.

The platform redesign also introduced a modern user interface and mobile applications, improving usability and adoption potential across clinical and educational settings. These developments align with the Group’s focus on software commercialisation and scalability.

Corporate Actions and Governance

Singular Health divested its non-core 3D printing operations in September 2024, streamlining its business to concentrate on software innovation. The Group maintained key quality certifications, including ISO13485 and MDSAP, and is progressing additional regulatory clearances such as FDA approval for its online viewer.

Post-year-end, the company appointed Dr. Alex Alonso, a Florida-based radiologist, as a US clinical advisor to support integration efforts and deployment within his practice, further strengthening its US market presence.

Outlook

With a robust capital base and strategic partnerships in place, Singular Health is positioned to accelerate the commercialisation of its 3DICOM solution in the US and other key markets. The company’s focus will be on delivering measurable outcomes from the PNS contract, expanding adoption across healthcare and education sectors, and continuing technology innovation to enhance shareholder value.